Unique ID issued by UMIN | UMIN000035908 |
---|---|
Receipt number | R000040886 |
Scientific Title | A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract |
Date of disclosure of the study information | 2019/02/18 |
Last modified on | 2019/05/14 09:21:47 |
A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract
A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract
A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract
A randomized, placebo-controlled, double-blind, parallel-group trial of observations of subjective and objective symptoms of eye fatigue and testing for improvement with the ingestion of bilberry extract
Japan |
Healthy subjects
Adult |
Others
NO
The objective of this study is to investigate the effect of the test food on eye function in healthy Japanese men and women aged 25 years or older and 40 years or younger who have continued to consume the test food for 4 weeks.
Efficacy
Visual fatigue
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
4-week intake of the containing bilberry extract food of 1 capsule a day
4-week intake of the placebo food of 1 capsule a day
25 | years-old | <= |
40 | years-old | >= |
Male and Female
1) Healthy Japanese men and women aged 25 to 40 years
2) People who feel tired of their eyes
3) Persons who routinely perform PC (PC) tasks or driving a car
4) Persons who have not undergone LASIK surgery (myopia correction surgery)
5) Subjects with uncorrected visual acuity of 0.2 or better at both eyes.
6) Persons who can be contacted by personal computers or smartphones
7) Persons with a BMI of 25 kg/m2 or less
8) People who can play games with smartphones for about 30 minutes
9) Subjects who are able to discontinue eye drops during the study period"
1) Patients who are currently receiving any medications or outpatient
2) Subjects currently undergoing exercise or diet therapy under the supervision of a physician
3) Persons with a history or current disease or complication of liver disease or serious diseases of renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic origin.
4) Persons who have been treated or had a history of chronic disease (arrhythmia, liver, kidney, cerebrovascular disease, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or other chronic diseases)
5) Persons who have had surgery of the digestive tract (appendicitis is allowed)
6) People who have pollinosis
7) Patients with ocular diseases other than refractive errors (hyperopia, myopia, astigmatism)
8) Persons with a history of drug allergy or food allergy
9) Those who wish to do so during pregnancy, lactation, or the study period.
10) Those who have received blood donations or vaccinations within the previous three months or who are scheduled to do so during the study period.
11) Persons who regularly consume health foods, supplements, and medicines that may affect eye function.
12) Persons who are in hospital due to mental disorders (depression etc.), sleeping disorders, etc., or who have a past medical history in the past.
13) Persons who are under treatment or have a history of alcohol dependence, drug dependence or drug abuser.
14) Person who is in shift work such as night work
15) Extremely irregular lifestyle, such as eating and sleeping
16) Current smokers
17) Subjects who have participated in other clinical trials or are currently participating in other clinical trials within the past 3 months of the date of informed consent.
18) Persons who have difficulty complying with the records of various surveys
19) Other persons for whom the principal investigator judges it inappropriate for the study.
"
36
1st name | Kosehira |
Middle name | |
Last name | Marie |
Omnica Co.,Ltd
Research and development Dept.
112-0002
TN Koishikawa BLDG. 5F, 1-15-17 Koishikawa, Bunkyo-ku, Tokyo, JAPAN
03-5840-9815
kosehira@omnica.co.jp
1st name | Daisuke |
Middle name | |
Last name | Ochitani |
HUMA R&D CORP
Clinical Development Division
108-0014
Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan
03-3431-1260
ochitani@huma-rd.co.jp
HUMA R&D CORP
Omnica Co.,Ltd
Profit organization
Japan
Ethics Committees of Nihonbashi Egawa Clinic
2F Kotobuki Build. 1-27-12 Yaesu Chuo-ku, Tokyo 103-0028 Japan
03-5204-0311
jim@medipharma.co.jp
NO
2019 | Year | 02 | Month | 18 | Day |
Unpublished
37
Completed
2019 | Year | 01 | Month | 11 | Day |
2019 | Year | 01 | Month | 15 | Day |
2019 | Year | 02 | Month | 14 | Day |
2019 | Year | 04 | Month | 06 | Day |
2019 | Year | 04 | Month | 08 | Day |
2019 | Year | 04 | Month | 28 | Day |
2019 | Year | 08 | Month | 31 | Day |
2019 | Year | 02 | Month | 18 | Day |
2019 | Year | 05 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040886
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |